In Grade II-III tumours, there was a 4-fold decrease in the EXT1 expression level, though the EXT2 expression was maintained, whereas in GBM tissues (Grade IV) the EXT2 expression level was decreased by 3–4-fold as well (p < 0.05). The gene discussed is EXT1; the disease is glioblastoma.